birc3 loss accelerates leukemic progression in cll
Published 5 years ago • 242 plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
2:01
the evolution of bcl2 inhibition in cll
-
3:14
understanding cll pathogenesis by assessing clonotypes
-
2:49
assessing parameters and standardising biomarker detection in cll
-
1:07
primary findings from the epcore cll-1 trial of epcoritamab in cll and rt
-
8:57
outcomes of sct in t-all and t-lbl
-
1:11
patient selection in the treatment of cll
-
1:24
sequencing of btk inhibitors in cll
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
3:58
chronic lymphocytic leukemia (cll) - diagnosis and treatment- hematology and oncology series
-
2:15
cdk9 inhibition with voruciclib for treating aml and r/r b-cell nhl
-
1:25
advances in targeted therapies and combination approaches for the treatment of cll
-
1:41
the role of pi3k inhibitors in cll
-
2:26
outcomes of ven-based regimens in cll/sll following intolerance or progression on covalent btki's
-
1:28
the future of cll treatment
-
2:20
murano: venetoclax rituximab in birc3-mutated r/r cll
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
3:29
how the management of cll is evolving
-
1:04
defining high-risk cll: known and emerging mutations
-
2:44
the structure and function of bcrs in the biology of cll
-
1:22
the future of cll treatment and more personalized approaches
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients